IFNA1 and infection: Specifically, TRL3D3, a human mAb against the G protein CCD, enhanced IFN responses, decreased airway inflammation, and improved lung function upon secondary infection, whereas mice treated with an anti-F mAb (palivizumab) had less IFN than mock infected mice (30, 33).